Drugs / FCTX-CL19-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06593145 | May 2023 → Jun 2025 overdue | acute lymphoblastic leukemia, large B-cell lymphoma, mantle cell lymphoma | FamiCordTx | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FCTX-CL19-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06593145 ↗ |
| Known as | Tarcidomgen Kimleucel | “study medicinal product FCTX-CL19-1 (Tarcidomgen Kimleucel)” NCT06593145 ↗ |
| Modality | Cell therapy | “containing autologous anti-CD19 CAR T cells” NCT06593145 ↗ |
| Route | Intravenous | “administration route - intravenous” NCT06593145 ↗ |
| Target | CD19 | “containing autologous anti-CD19 CAR T cells” NCT06593145 ↗ |